Serum RIPK3/MLKL as exploratory biomarker candidates for systemic lupus erythematosus

Abstract

Objective

This study aims to elucidate the novel role of serum receptor interacting protein kinase 3 (RIPK3)/mixed series of protein kinase-like domains (MLKL) levels in SLE and assess their correlation with clinical manifestations and serological parameters.

Methods

We employed enzyme-linked immune sorbent assay (ELISA) analysis to evaluate RIPK3/MLKL protein levels in serum from 90 SLE patients and 50 healthy controls (HC).

Results

Our findings reveal a significant elevation of serum RIPK3/MLKL protein levels in SLE patients compared to HC (p = 0.0004 and p = 0.0005, respectively). Notably, these levels were closely associated with the disease’s clinical manifestations, notably heightened in active SLE compared to stable cases (p = 0.0312 and p = 0.0096, respectively). Furthermore, while RIPK3 protein exhibited significant upregulation in patients with lupus nephritis (LN) compared to non-LN individuals (p = 0.0017). SLE patients with high anti-nuclear antibody (ANA) titers exhibited notably higher RIPK3 levels compared to those with low ANA titers (p < 0.0001). The receiver operating characteristic (ROC) curve demonstrated diagnostic potential for serum RIPK3/MLKL, with respective areas under the curve (AUCs) of 0.6319 (p = 0.0099) and 0.7374 (p < 0.0001).

Conclusions

Our study illuminate serum RIPK3/MLKL proteins are exploratory biomarker candidates for SLE and necroptosis may be involved in SLE pathogenesis.

Keywords

RIPK3 protein MLKL protein necroptosis systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Tian

Zhang

Yao

, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis 2023; 82(3): 351–356. https://doi.org/10.1136/ard-2022-223035

Sawada

Fujimori

Yamamoto

. Systemic lupus erythematosus and immunodeficiency. Immunol Med 2019; 42(1): 1–9. https://doi.org/10.1080/25785826.2019.1628466

Zhao

, et al. Dysregulation of cell death and its epigenetic mechanisms in systemic lupus erythematosus. Molecules 2016; 22(1): 30. https://doi.org/10.3390/molecules22010030

Sarhan

Liu

Muendlein

, et al. Constitutive interferon signaling maintains critical threshold of MLKL expression to license necroptosis. Cell Death Differ 2019; 26(2): 332–347. https://doi.org/10.1038/s41418-018-0122-7

Someda

Kuroki

Miyachi

, et al. Caspase-8, receptor-interacting protein kinase 1 (RIPK1), and RIPK3 regulate retinoic acid-induced cell differentiation and necroptosis. Cell Death Differ 2020; 27(5): 1539–1553. https://doi.org/10.1038/s41418-019-0434-2

Yue

Cao

, et al. Pretreatment with 3-methyladenine ameliorated pseudomonas aeruginosa-induced acute pneumonia by inhibiting cell death of neutrophils in a mouse infection model. Int J Med Microbiol 2023; 313(2): 151574. https://doi.org/10.1016/j.ijmm.2023.151574

Liu

, et al. Pulmonary Staphylococcus aureus infection regulates breast cancer cell metastasis via neutrophil extracellular traps (NETs) formation. MedComm 2020; 1(2): 188–201. https://doi.org/10.1002/mco2.22

Zhang

Jie

, et al. Increased MLKL mRNA level in the PBMCs is correlated with autoantibody production, renal involvement, and SLE disease activity. Arthritis Res Ther 2020; 22(1): 239. https://doi.org/10.1186/s13075-020-02332-7

Guo

Zhou

, et al. Pathogenesis of lupus nephritis: RIP3 dependent necroptosis and NLRP3 inflammasome activation. J Autoimmun 2019; 103: 102286. https://doi.org/10.1016/j.jaut.2019.05.014

10.

Aringer

Costenbader

Daikh

, et al. 2019 European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019; 78(9): 1151–1159. https://doi.org/10.1136/annrheumdis-2018-214819

11.

Golder

Tsang-A-Sjoe

MWP

. Treatment targets in SLE: remission and low disease activity state. Rheumatology 2020; 59(Suppl5): v19–v28. https://doi.org/10.1093/rheumatology/keaa420

12.

Tang

Kang

Zeh

, et al. The multifunctional protein HMGB1: 50 years of discovery. Nat Rev Immunol 2023; 23(12): 824–841. https://doi.org/10.1038/s41577-023-00894-6

13.

Morgan

Kim

. Roles of RIPK3 in necroptosis, cell signaling, and disease. Exp Mol Med 2022; 54(10): 1695–1704. https://doi.org/10.1038/s12276-022-00868-z

14.

Crow

. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis 2023; 82(8): 999–1014. https://doi.org/10.1136/ard-2022-223741

15.

, et al. Pathological mechanisms and crosstalk among different forms of cell death in systemic lupus erythematosus. J Autoimmun 2022; 132: 102890. https://doi.org/10.1016/j.jaut.2022.102890

16.

Yang

Zhai

, et al. Programmed cell death pathways in the pathogenesis of systemic lupus erythematosus. J Immunol Res 2019; 2019: 3638562. https://doi.org/10.1155/2019/3638562

17.

Muendlein

Sarhan

Liu

, et al. Constitutive interferon attenuates RIPK1/3-Mediated cytokine translation. Cell Rep 2020; 30(3): 699–713.e4. https://doi.org/10.1016/j.celrep.2019.12.073

18.

Parikh

Almaani

Brodsky

, et al. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis 2020; 76(2): 265–281. https://doi.org/10.1053/j.ajkd.2019.10.017

19.

Kolbrink

von Samson-Himmelstjerna

Murphy

, et al. Role of necroptosis in kidney health and disease. Nat Rev Nephrol 2023; 19(5): 300–314. https://doi.org/10.1038/s41581-022-00658-w

20.

Lou

Ling

Cao

. Autoantibodies in systemic lupus erythematosus: from immunopathology to therapeutic target. J Autoimmun 2022; 132: 102861. https://doi.org/10.1016/j.jaut.2022.102861

21.

Salem

Subang

Pernet

, et al. Necroptotic cell binding of β2 -glycoprotein I provides a potential autoantigenic stimulus in systemic lupus erythematosus. Immunol Cell Biol 2019; 97(9): 799–814. https://doi.org/10.1111/imcb.12279

22.

Chen

Zou

Kang

, et al. The redox protein high-mobility group box 1 in cell death and cancer. Antioxidants Redox Signal 2023; 39(7–9): 569–590. https://doi.org/10.1089/ars.2023.0236

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.07 MB